StockData
Kestra Medical Technologies, Ltd. logo

Kestra Medical Technologies, Ltd. (KMTS) stock

KMTSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 14, 2026Score 5/30
$28.27+0.30 (+1.07%)

Close on Nov 17, 2026Market cap $1.68BP/E –Yield –

Kestra Medical Technologies r&d expenses

Research and development expenses are spending on new products and technology.

Kestra Medical Technologies's R&D Expenses for the twelve months ending Jul 31, 2026 was $22.28M, up 37.1% year over year. For fiscal 2026 it was $19.48M, up 24.5% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2026Apr 30, 2026$19.48M+24.5%
FY2025Apr 30, 2025$15.65M+1.0%
FY2024Apr 30, 2024$15.49M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jul 31, 2026$6.80M+69.9%
Q4 FY2026CQ1 2026Apr 30, 2026$5.63M+4.6%
Q3 FY2026CQ4 2025Jan 31, 2026$4.97M+48.3%
Q2 FY2026CQ3 2025Oct 31, 2025$4.88M+39.0%
Q1 FY2026CQ2 2025Jul 31, 2025$4.00M+17.5%
Q4 FY2025CQ1 2025Apr 30, 2025$5.39M–
Q3 FY2025CQ4 2024Jan 31, 2025$3.35M–
Q2 FY2025CQ3 2024Oct 31, 2024$3.51M–
Q1 FY2025CQ2 2024Jul 31, 2024$3.40M–

More Kestra Medical Technologies figures

See a number that looks wrong?